# GLP-1s for $50 a Month? 14 Million Medicare Recipients May Be Eligible
Medicare has expanded access to GLP-1 medications like semaglutide and tirzepatide for seniors, potentially lowering costs to $50 per month for eligible beneficiaries. About 14 million Medicare recipients qualify for this pricing through the program's drug cost-sharing provisions.
GLP-1 receptor agonists have become popular treatments for type 2 diabetes and weight management. These drugs, sold under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, typically cost hundreds of dollars monthly without insurance. The new Medicare pricing brings them within reach for many older adults on fixed incomes.
Eligibility depends on enrollment in a Medicare Part D prescription drug plan with coverage for GLP-1s. Beneficiaries must have already paid into their plan's deductible and fallen within specific cost-sharing tiers. Most plans cap annual out-of-pocket drug expenses, with the $50 monthly cost applying once patients reach certain spending thresholds.
This shift reflects mounting pressure on Medicare to address medication affordability. The program previously negotiated lower prices for select drugs, but GLP-1s represented a gap. Aging populations experience high rates of type 2 diabetes, making access to effective treatments a health priority.
Seniors should review their current Medicare Part D plan to confirm GLP-1 coverage. Some plans cover semaglutide but not tirzepatide, or vice versa. Those in plans without GLP-1 coverage can switch during the annual enrollment period, which runs October 15 through December 7 each year.
Doctors caution that GLP-1s work best when combined with lifestyle changes. These medications carry side effects like nausea and